
Trellus Health plc
("Trellus Health" or the "Company")

Directorate Changes

LONDON, UK. AND NEW YORK, U.S. (7 June 2024) Trellus Health plc (AIM: TRLS), a health services company delivering innovative, scientifically validated programs and technologies designed to facilitate the management of chronic conditions, improve health outcomes and lower the costs of care, announces the appointment of Kevin L. Murphy Jr. as an independent Non-executive Director, effective immediately, and as Chair Designate. It is intended that Kevin will replace Dr. Daniel Mahony as Chair, on the conclusion of the board meeting to be held immediately after the Company's forthcoming annual general meeting on 14 June 2024. This is consistent with the previously announced, planned evolution of the Board to include a new director with experience of the US healthcare industry, and follows Dr. Mahony's acceptance of a new role as Senior Partner at Novo Holdings which requires him to relinquish his pre-existing Board roles.

Kevin Murphy is an experienced healthcare executive, having worked as a P&L leader for both large and small organisations in the healthcare, insurance and pharmacy industries. Kevin's expertise includes strategy development and execution, clinical programme delivery, driving revenue and margin expansion, acquisitions, integrations, joint ventures, and new product and market /commercial development.

Kevin recently retired from CVS Health Corporation ("CVS Health"), a Fortune 500 healthcare company providing advanced health care from pharmacy services and health plans, to health and wellness. At CVS Health, he spent over ten years in various roles. Kevin joined CVS Health as President of Accordant, which delivers personalised healthcare advice to members and their caregivers through the support of nurse teams and support staff, while reducing overall health care costs. There, he led a significant turnaround which included reorganising the clinical care delivery model, upgrading Accordant's core operating systems and opening new markets and distribution channels, resulting in an increase in revenues and EBIT. Subsequently, Kevin spent five years as Group Head Specialty and Infusion at CVS Health, which included negotiating and acting as business lead for the \$2.1B acquisition of Coram; in 2019, Kevin was appointed Senior Vice President, Payer Relations and Managed Care.

Prior to joining CVS Health, Kevin held P&L leadership roles at Medco, the largest pharmacy benefits management company in the US, and Physicians Health Services, a regional health insurance group.

Kevin graduated with a B.S. in Management from University of Rhode Island and an M.S. in Finance from Fairfield University.

Dr. Marla Dubinsky, CEO and Co-Founder of Trellus Health, said: "I am delighted to welcome Kevin to the Board of Trellus Health. We have been looking to appoint a director with experience in the US healthcare industry, and Kevin's expertise in strategy and care delivery within this space, will be hugely valuable to us as we continue to progress the commercialisation of Trellus Elevate™. On behalf of the Company, I would like to thank Dan for his valuable contributions, particularly in his role as Chair, and wish him all the best in his new role."

Kevin Murphy, newly appointed Non-executive Director and Chair Designate of Trellus Health, said: "Trellus Health's innovative approach to US healthcare aligns well with my experience, and I believe the Trellus Elevate™ program can improve outcomes for those living with chronic conditions while lowering the cost of care. I look forward to working with the team to help the Company roll out Trellus Elevate™ to as many people as possible."

Dr. Daniel Mahony, Non-executive Chair of Trellus Health, said: "I have enjoyed working as part of the Trellus Health Board, as the Company progressed and secured its first commercial-scale B2B2C contract and continues to progress other opportunities. Having been part of the team to recruit Kevin, I am confident that he will be an excellent Chair for the Company, and that his extensive US healthcare experience will prove invaluable."

Regulatory Disclosures

Kevin Laurence Murphy Jr. (aged 64) is currently or has been a director of the following companies within the previous five years:

Current directorships/partnerships

- Blue Cross & Blue Shield of Rhode Island
- The American Lung Association of the NorthEast Inc
- KLM Healthcare LLC

Past directorships/partnerships

N/A

The Company confirms that Kevin Murphy is eligible to participate in the US sub-plan of its Share Option Plan and will be granted options in relation to his service with the Company, in line with the Company's remuneration practise in due course.

Save as disclosed above, there is no further information to be disclosed in respect of the appointment, pursuant to Rule 17 and Schedule 2 paragraph (g) of the AIM Rules for Companies.

For further information please contact:

Trellus Health plc
Dr. Marla Dubinsky, CEO and Co-Founder

<https://trellushealth.com/>
Via Walbrook PR

Joy Bessenger, CFO

Singer Capital Markets (Nominated Adviser and Broker)
Aubrey Powell / Jen Boorer / Jalini Kalaravy

Tel: +44 (0)20 7496 3000

Walbrook PR
Paul McManus / Sam Allen / Phillip Marriage

Tel: +44 (0)20 7933 8780 or trelus@walbrookpr.com
Mob: +44 (0)7980 541 893 / 07748 651 727 / 07867 984 082

This announcement contains inside information for the purposes of the retained UK version of the EU Market Abuse Regulation (EU) 596/2014 ("UK MAR").

About Trellus Health plc (www.trellushealth.com)

Trellus Health (AIM: TRLS) is a health services company providing value-based innovative solutions and services for chronic condition management that prioritises improved outcomes and member experiences while managing costs of care.

Trellus Health integrates its proprietary resilience-based methodology with the technology, tools, and expert coaching and educator team to deliver Trellus Elevate™, a whole-person technology-enhanced experience that meets each individual's unique needs and empowers them to master their physical and emotional health. Trellus Elevate's™ clinically proven solutions result in relieving disease burden, building self-management skills and promoting positive health behaviours that improve outcomes and enables thriving in the face of a chronic condition.

The Company's proven whole person approach recognises the interconnectedness of various aspects of a person's life and aims to address the whole spectrum of factors that influence behaviour, to promote comprehensive well-being and human flourishing in a way that aligns with value-based care. Trellus Health's approach enables better health outcomes in a member-centric, personalised and comprehensive holistic solution.

The Company was founded by Mount Sinai faculty members Marla C. Dubinsky, MD and Laurie Keefer, PhD, both experts at treating and healing both the physical and emotional impacts of IBD and have been innovators for whole-person healthcare for a combined 50 years.

The Company is initially focusing on chronic costly GI conditions that have high mental health burden, such as inflammatory bowel disease ("IBD") which includes the chronic incurable conditions of Crohn's Disease and ulcerative colitis. Given the common emotional and mental health struggles often experienced by individuals suffering from a variety of chronic conditions, Trellus Health considers its approach to have potential utility and demand across many conditions.

The Trellus Elevate™ program incorporates the GRITT™ methodology and learnings on resilience from clinical research and practice conducted at the Mount Sinai IBD Center for more than seven years. This proprietary, resilience-driven methodology has been scientifically validated to demonstrate meaningful improvements in patient outcomes, 71% reduction in Emergency Department (A&E) visits, and 94% reduction in unplanned hospitalisations, which the directors of the Company believe indicates the potential for significant cost savings for healthcare payers and health systems. Patients with IBD managed with the proprietary resilience methodology also experienced a 49% reduction in required opioid use and a 73% reduction in corticosteroid use 12 months following starting the program which is a major indicator of improved health outcomes¹.

Shares in Trellus Health were admitted to trading on AIM in May 2021, under the ticker TRLS. For more information on Trellus Health, visit: www.trellushealth.com

¹ Source: <https://www.sciencedirect.com/science/article/pii/S1542356521012258>

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

BOAMZGGVMVKGDZZ